SDC - Gemini Therapeutics defended Cassava Sciences price target lifted; in today's analyst action

P_Wei/E+ via Getty Images Cassava Sciences is on recovery as B Riley lifts price target After a loss of ~13.5% yesterday, Cassava Sciences (SAVA) has recovered today rising ~2.6% in the premarket after B Riley Securities raised its price target to $111.00 from $78.00 per share implying a premium of ~43.0%. Reaffirming the buy rating, the analysts led by Mayank Mamtani argue that despite the recent outperformance, “there remains substantial room for upside” for Cassava shares given the near-term catalysts including the “evolving regulatory framework.” The company with an Alzheimer’s candidate simufilam in its pipeline rose sharply on the day Biogen received FDA approval for its Alzheimer’s therapy Aduhelm (aducanumab). SmileDirectClub cut to hold at Loop Capital on execution concerns SmileDirectClub (SDC) has lost ~2.7% in the early trading after Loop Capital Markets downgraded the stock to hold from buy. The price target lowered to $9.00 from $14.00 per share implies no premium. Citing execution

For further details see:

Gemini Therapeutics defended, Cassava Sciences price target lifted; in today’s analyst action